3 registrations that name bitter melon as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
All 3 registrations
RecruitingNCT07504029
Human Clinical Trial Evaluating the Blood Glucose-Regulating Effects of Momordica Charantia Peptides
No phase
Chung Shan Medical University
About 12 people
Started Mar 13, 2026
In plain words A study of bitter melon in people 30 to 65, run by Chung Shan Medical University. It plans to enroll about 12 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 30 to 65. Conditions: People With Prediabetic.
Adults aged 30-65 years, both male and female.
Participants meeting any of the following criteria for prediabetes:
Fasting blood glucose 100-125 mg/dL
HbA1c 5.7-6.4%
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
BmpP® Momordica charantia Peptide Capsules
Registered summary
Prediabetes is a metabolic condition characterized by elevated blood glucose levels that are higher than normal but below the diagnostic threshold for diabetes. Early intervention to improve glycemic control may help delay the progression to type 2 diabetes. Momordica charantia (bitter melon) peptides have been reported to possess potential glucose-regulating effects. This study aims to evaluate the effects of BmpP® bitter melon peptide supplementation on glycemic control in adults with prediabetes. This study is designed as a 12-week single-arm, open-label clinical trial. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
Not yet recruitingNCT06970834
Explore the Effect of Bitter Melon Peptides on Glycemic Control and Metabolic Indicators in Diabetic Patients
No phase
Changhua Christian Hospital
About 160 people
Starts May 27, 2025 (estimated)
In plain words A study of bitter melon in people 20 to 80, run by Changhua Christian Hospital. It plans to enroll about 160 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 20 to 80. Conditions: Diabetes.
What it tests, as registered
bitter melon peptides
Registered summary
The goal of this clinical trial is to learn the potential of bitter melon peptides in stabilizing blood glucose in diabetic adults. It will also learn about the effects of bitter melon peptides on metabolic parameters. The main questions it aims to answer are: * the regulatory effects of bitter melon peptides on glycemic variability * impact on glycemic and metabolic indicators Researchers will compare bitter melon peptides to a placebo (a look-alike capsule that contains Microcrystalline Cellulose) to see if bitter melon peptides works to stabilizing blood glucose. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07302178
Combined Bitter Melon Extract and Snakehead Fish Powder Supplementation for Glycemic Control in Type 2 Diabetes
No phase
Universitas Muhammadiyah Surakarta
About 80 people
Starts Jan 1, 2026 (estimated)
In plain words A study of bitter melon in people 20 to 65, run by Universitas Muhammadiyah Surakarta. It plans to enroll about 80 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 20 to 65. Conditions: Type 2 Diabetes Mellitus (T2DM); Hyperglycemia.
Diagnosed with Type 2 Diabetes Mellitus (DMT2).
Fasting plasma glucose ≥ 126 mg/dL and ≤ 200 mg/dL or random blood glucose between 200-300 mg/dL.
Age 20-65 years
Duration of diabetes 0-15 years.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Snakehead Fish Powder + Bitter Melon Extract; Placebo Capsule
Registered summary
Type 2 diabetes mellitus (T2DM) remains a major global health problem due to its high prevalence, long-term complications, and substantial economic burden. Conventional antidiabetic therapies, including insulin and oral hypoglycemic agents, may cause significant side effects during long-term use and are contraindicated in certain clinical conditions. Therefore, safe and effective herbal-based alternatives are needed. The full summary is on the listing.